Biosimilar Infliximab in inflammatory bowel diseases: First interim results from a prospective nationwide observational cohort
K Gecse, K Farkas, B Lovász, J Banai, L Bene, B Gasztonyi, P Golovics, T Kristóf, L Lakatos, P Miheller, F Nagy, K Palatka, M Papp, VÁ Patai, Á Salamon, T Szamosi, Z Szepes, T Tóth, Á Vincze, T Molnár, P Lakatos · Zeitschrift für Gastroenterologie · 2015 · Heft 05
Bibliografische Angaben
Zusammenfassung
Introduction: Biosimilars are biologic medicines that enter the market subsequent to an original reference product whose patent has expired. Biosimilar infliximab entered the Hungarian market in May 2014. Few data is yet available on the safety and efficacy of biosimilar infliximab in extrapolated indications, such as inflammatory bowel diseases. Methods: A prospective, nationwide, multicentre, observational cohort was designed to examine the safety and efficacy of CT- P13 infliximab biosimilar in induction and maintenance of remission in Crohn's disease (CD) and ulcerative colitis (UC). Demographic data were co…
